Beam Therapeutics (BEAM) Earnings Date & Reports

Key Takeaways

• Beam Therapeutics reported a third-quarter 2026 net loss of $134.4 million, or $1.28 per share, wider than the $112.6 million loss ($1.10 per share) a year earlier.
• License and collaboration revenue fell to roughly $307,000 from $9.7 million a year ago, well below the consensus estimate of around $8.75 million.
• Research and development (R&D) expenses were essentially flat at $110.1 million, while general and administrative (G&A) expenses rose about 17.9% to $31.5 million.
• The company held $1.0 billion in cash, cash equivalents, and marketable securities as of September 30, 2026, with runway projected into mid-2029.
• Pipeline momentum remained the central focus, with a potential Biologics License Application (BLA) for risto-cel targeted as early as year-end 2026.
• For more on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages on Tickeron.
• Discover fresh trade ideas and market signals by exploring Trending AI Robots.

Earnings Context and Why It Matters

Beam Therapeutics is a clinical-stage biotechnology company developing precision genetic medicines using base editing, a gene-editing technique designed to make precise, single-letter DNA changes without cutting both strands of the genome. Because it has no approved products yet, its quarterly results are driven less by revenue than by clinical execution, cash runway, and spending discipline. The third-quarter update carried extra weight because the company is approaching a potential first regulatory filing for risto-cel in sickle cell disease (SCD) while advancing multiple other programs, including BEAM-302 for alpha-1 antitrypsin deficiency (AATD). For investors, the report was a checkpoint on whether Beam can fund its growing pipeline through key value-inflection milestones without near-term dilution.

Reported Results

For the third quarter ended September 30, 2026, Beam Therapeutics reported a net loss of $134.4 million, or $1.28 per share, compared with a net loss of $112.6 million, or $1.10 per share, in the prior-year period. The result was wider than the consensus estimate of a loss of roughly $1.15 per share. License and collaboration revenue came in at about $307,000, down sharply from $9.7 million a year earlier and below analyst expectations near $8.75 million, reflecting the lumpy, milestone-driven nature of collaboration income for a company without approved products.

R&D expenses held nearly flat at $110.1 million versus $109.8 million, while G&A expenses increased to $31.5 million from $26.7 million as Beam builds out its commercial organization. The company ended the quarter with $1.0 billion in cash, cash equivalents, and marketable securities, down from $1.2 billion at the end of 2025, and expects this balance, together with an additional $200 million to be drawn from its Sixth Street facility, to fund operations into mid-2029.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Whether you are researching earnings-driven moves or tracking momentum in the biotech sector, the AI Screener offers a streamlined way to surface relevant candidates and refine your watchlist.

Market Reaction and Investor Sentiment

Beam shares came under pressure in the session following the release, as the wider-than-expected quarterly loss and the sizable revenue shortfall weighed on sentiment. For a clinical-stage biotech, however, quarterly revenue misses tied to collaboration milestone timing carry less informational weight than pipeline and cash-position updates. Investor attention quickly shifted to the clinical narrative: the company reiterated plans to report updated risto-cel data and submit a U.S. BLA as early as year-end 2026, and to complete dosing in the pivotal BEAM-302 cohort in the first half of 2027. The multi-year cash runway also helped temper concerns about near-term dilution, even as rising G&A spending signaled investment in a future commercial launch.

Forward Outlook and Key Factors to Monitor

The most closely watched near-term catalyst is the potential BLA submission for risto-cel in sickle cell disease, targeted for as early as the end of 2026. Investors will be watching for updated clinical data and any signals from the U.S. Food and Drug Administration (FDA) about the regulatory path forward.

Beyond risto-cel, the BEAM-302 program for AATD remains a key focus. Updated Phase 1/2 data presented in September 2026 showed durable increases in functional AAT and reductions in mutant Z-AAT with up to 18 months of follow-up, and completion of dosing in the global pivotal cohort is expected in the first half of 2027.

Early BEAM-301 data in glycogen storage disease type Ia showed dose-dependent improvements in time to fasting hypoglycemia, and Beam is now enrolling a higher 60 mg cohort while planning FDA engagement. Meanwhile, dosing in the Phase 1/2 trial of BEAM-304 for phenylketonuria (PKU) is anticipated to begin in early 2027.

Financially, investors should monitor how quickly the $1.0 billion cash balance is deployed across four advancing programs, whether the Sixth Street drawdown conditions are met, and how G&A costs trend as the company builds toward a potential commercial launch. Clinical or regulatory delays, as well as shifts in the competitive genetic-medicine landscape, remain among the primary risks to watch.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations